Corvus Pharmaceuticals Reports Positive Phase 1 Data for Soquelitinib, Secures $189M Financing

Event summary

  • Corvus reported positive safety and efficacy data from cohort 4 of the Phase 1 trial for soquelitinib in atopic dermatitis, including 75% of patients achieving EASI 75.
  • The company initiated a Phase 2 trial for soquelitinib in atopic dermatitis and plans to start Phase 2 trials in asthma and hidradenitis suppurativa later in 2026.
  • Corvus completed a public offering raising $189 million, extending its cash runway into Q2 2028.
  • The Phase 3 trial for soquelitinib in relapsed/refractory peripheral T cell lymphoma (PTCL) is ongoing, with no FDA-approved agents currently available for this indication.

The big picture

Corvus Pharmaceuticals is advancing its lead candidate, soquelitinib, through multiple clinical trials targeting both oncology and immune diseases. The recent financing provides a strong cash position to support these trials, but the company's success will hinge on demonstrating consistent efficacy and safety across different indications. The biotech sector is increasingly focused on precision immunotherapies, and Corvus' ITK inhibition approach could position it as a key player if clinical milestones are met.

What we're watching

Clinical Progress
Whether the Phase 2 trial for soquelitinib in atopic dermatitis can replicate the positive results seen in the Phase 1 trial, particularly in patients resistant to existing therapies.
Financial Strategy
How Corvus will allocate the $189 million in proceeds to advance its pipeline, including the Phase 3 PTCL trial and upcoming Phase 2 trials in asthma and hidradenitis suppurativa.
Regulatory Pathway
The pace at which Corvus can secure regulatory approvals for soquelitinib, given its Orphan Drug and Fast Track designations for PTCL and the potential for broader indications in immune diseases.